These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 10976656)

  • 21. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
    Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
    Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
    Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
    J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.
    De Vos M; Verdievel H; Schoonjans R; Praet M; Bogaert M; Barbier F
    Gut; 1992 Oct; 33(10):1338-42. PubMed ID: 1446856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
    Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
    Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
    Hussain FN; Ajjan RA; Riley SA
    Br J Clin Pharmacol; 2000 Apr; 49(4):323-30. PubMed ID: 10759687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis.
    Gionchetti P; Venturi A; Rizzello F; Corbelli C; Fanti S; Ferretti M; Boschi S; Miglioli M; Campieri M
    Aliment Pharmacol Ther; 1997 Aug; 11(4):679-84. PubMed ID: 9305475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
    Harris MS; Lichtenstein GR
    Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
    Støa-Birketvedt G; Florholmen J
    Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review: the use of mesalazine in inflammatory bowel disease.
    Bergman R; Parkes M
    Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution and anti-inflammatory effect of mesalazine on carrageenan-induced colitis in the rabbit.
    Kitano A; Matsumoto T; Oshitani N; Nakagawa M; Yasuda K; Watanabe Y; Tomobuchi M; Obayashi M; Tabata A; Fukushima R; Okabe H; Nakamura S; Obata A; Okawa K; Kobayashi K
    Clin Exp Pharmacol Physiol; 1996 Apr; 23(4):305-9. PubMed ID: 8717066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
    Klotz U
    Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
    McKeage K; Goa KL
    Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study.
    Kruis W; Leifeld L; Morgenstern J; Pfützer R; Reimers B; Ceplis-Kastner S;
    J Crohns Colitis; 2013 May; 7(4):e125-32. PubMed ID: 22951030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions.
    Jacobsen BA; Abildgaard K; Rasmussen HH; Christensen LA; Fallingborg J; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1991 Apr; 26(4):374-8. PubMed ID: 2034991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease.
    Suzuki Y; Iida M; Ito H; Tachikawa N; Hibi T
    Drugs R D; 2016 Mar; 16(1):35-43. PubMed ID: 26883035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1992 Oct; 27(10):863-8. PubMed ID: 1359629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.